Trial · NCT02338531
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
NCT02338531, Phase 2, Withdrawn, Jules Bordet Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer. Trials, record NCT02338531. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02338531
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
- NCT number
- NCT02338531
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Jules Bordet Institute
- Conditions
- Breast Cancer
- Interventions
- PF-03084014, Breast cancer surgery
- First posted
- 2015-01-14
- Last updated
- 2016-04-29
- Other registries' IDs
- eudract:2014-004358-32
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HES4 gene expression level | tumour tissue samples before study drug and after 9 days of study drug. General analysis after all patients included. | To demonstrate that PF-03084014 is able to modulate the Notch pathway by down-regulating the expression of the tumor HES4 gene in chemoresistant TNBC (evaluable population). |
| Secondary | Safety: General assesment of number and grade of adverse events after short(9-day) administration of oral PF-03084014 in patients with chemoresistant TNBC. | adverse events followed up to 28 days after last PF-03084014 dose. | Patients will be followed for Adverse Events and Serious Adverse Events from the first dose of study drug up to 28 days after the last dose. |
| Secondary | Transcriptome analysis (changes in the HES4 gene expression and tumor transcriptome) | tissue samples before study drug and after 9 days of study drug. General analysis after all patients included. | To assess changes in the HES4 gene expression and tumor transcriptome for all patients registered in the RHEA study (intent-to-treat population) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02338531
GET https://conductscience.org/api/trials/v1/NCT02338531/registered